Asthma did not increase in‐hospital COVID‐19‐related mortality in a tertiary UK hospital

Abstract

To the Editor, Asthma is the most prevalent chronic inflammatory respiratory disease worldwide affecting one in twelve adults (8.3%) in the United Kingdom (UK). 1 Coronavirus disease 2019 (COVID-19) has afflicted at least 80.3 million patients worldwide (17.3 million in the EU, 2.3 million in the UK) and has resulted in more than 1.6 million deaths (427,000 in the EU, 71,000 in the UK) (European Centre for Disease Prevention and Control: 30/12/2020). It is still unclear how asthma affects COVID-19-related mortality with marked regional differences noted. 2 Comorbid associations of COVID-19 with asthma were significantly lower than the prevalence of asthma in

Meta-Analysis the Effect of Asthma Comorbidity on the Mortality of COVID-19 Patients

“…The results of the study were in line with those conducted by Almazeedi et al (2020) which stated that asthma comorbidity was a risk factor for mortality in COVID-19 patients in Kuwait (aOR= 4.92; CI 95%= 1.03 to 23.44; p= 0.046). Other similar studies were found in the UK (Fong et al, 2021), South America (Mato et al, 2020), Turkey (Trabulus et al, 2021) and Spain (Almirall et al, 2020).…”

Risk of serious COVID-19 outcomes among adults with asthma in Scotland: a national incident cohort study

“…[7][8][9][10][11][12] No association was observed between severe asthma and COVID-19 deaths in one study, which could have been because of the small study sample size, which only included data from a single English hospital. 25 Particularly high risks of COVID-19 hospital admission, ICU admission, and death have been reported in patients with asthma using high doses of inhaled corticosteroids and those with recent oral corticosteroid use for asthma (in the past 1-2 years). [7][8][9]12 Our study has contributed to UK evidence using nationwide population-level data and quantified the strength of associations between history of an asthma attack in the preceding 2 years and markers of severe COVID-19 outcomes across different waves of the COVID-19 pandemic, accounting for vaccination status.…”

Risk of serious COVID-19 outcomes among adults and children with moderate-to-severe asthma: a systematic review and meta-analysis

“…Three studies presenting odds ratios were included in a separate meta-analysis, which showed OR 1.07 (95% CI 0.15-7.82, I 2 =30%) (supplementary figure E3) [20,23,26]. When six aHRs were included in the meta-analysis [15][16][17][18][19]25], severe asthma in adults was not associated with a higher aHR (1.22, 95% CI 0.90-1.65; I 2 =70%) (figure 2c). The pooled aHR derived from four population-based cohorts [15,18,19,25] was 1.10 (95% CI 0.84-1.46), with moderately high heterogeneity (I 2 =66%) (figure 3a).…”

“…Out of 2649 records identified after deduplication, 317 underwent full-text screening. Of these, 12 studies were retained for data extraction [15][16][17][18][19][20][21][22][23][24][25][26]. The screening process is summarised in a PRISMA flow chart (figure 1).…”

“…For high-dose ICS, four studies were included in analysis (figure 3b). Use of high-dose ICS had an aHR of 1.42 in adults, compared to those with mild or no asthma (aHR 1.42, 95% CI 0.84-2.40; I 2 =75%) [15][16][17][18]. When dividing the studies by settings again, two population-based cohort studies [15] showed an aHR of 1.27 (95% CI 0.11-14.76, I 2 =78%) and two hospital-based studies [16,17] showed an aHR for death from COVID-19 of 1.96 (95% CI 0.12-31.28, I 2 =0%) compared to those with nonsevere or no asthma.…”